Implications of Prognostic Factors and Risk Groups in the Management of Differentiated Thyroid Cancer

Laryngoscope

Volumn 114, Issue 3, 2004, Pages 393-402

  Shaha, Ashok R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Prognosis; Surgical treatment; Thyroid cancer

Indexed keywords

AGE; ARTICLE; BEAM THERAPY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SIZE; CANCER STAGING; CATHETER ABLATION; HIGH RISK POPULATION; HUMAN; LOBECTOMY; METASTASIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; THYROID CANCER; THYROIDECTOMY; TREATMENT OUTCOME;

ADULT; AGED; DECISION TREES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 1642392071     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-200403000-00001     Document Type: Article

References (50)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma: a study of the EORTC Thyroid Cancer Cooperative Group. Eur J Cancer 1979;15:1033-1041.
3. Cady B, Ross R, Silverman M, Wool M. Further evidence of the validity of risk-group defmition in differentiated thyroid gland. Surgery 1985;98:1171-1178.
4. Cady B, Sedgewick CE, Meissner WA, Wool MS, Salzman FA, Werber J. Risk factor analysis in differentiated thyroid cancer. Cancer 1979;43:810-819.
5. Cady B, Ross R. An expanded view of risk group definition in differentiated thyroid carcinoma. Surgery 1988;104:947-953.
6. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987;102:1088-1095.
7. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993;114:1050-1058.
8. Hay ID, Taylor WF, McConahey WM. A prognostic score for predicting outcome in papillary thyroid carcinoma. Endocrinology 1986;119(Suppl):1-15.
9. Shaha A, Loree TR, Shah JP. Intermediate-risk group for differentiated carcinoma of the thyroid. Surgery 1994;116:1036-1041.
10. Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 1995;118:1131-1138.
11. Gilliland FD, Hunt WC, Morris DM, et al. Prognostic factors for thyroid carcinoma: a population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program, 1973-1991. Cancer 1997;79:564-573.
12. Hay ID, Grant CS, Bergstralh EJ, et al. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery 1998;124:958-966.
13. Brierley JD, Panzarella T, Tsang RW, et al. Review: a comparison of different staging systems predictability of patient outcome-thyroid carcinoma as an example. Cancer 1997;79:2414-2423.
14. Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome - National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 1998;83:1012-1021.
15. Cady B. Staging in thyroid carcinoma. Cancer 1998;83:844-847.
16. Cady B. Hayes Martin Lecture. Our AMES is true: how an old concept still hits the mark, or risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg 1997;174:462-468.
17. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-428.
18. Shaha AR, Shah JP, Loree TR. Low-risk differentiated thyroid cancer: the need for selective treatment. Ann Surg Oncol 1997;4:328-333.
19. Mazzaferri EL. Review: papillary thyroid carcinoma-factors influencing prognosis and current therapy. Semin Oncol 1987;14:315-332.
20. Akslen LA, et al. Prognostic importance of various clinicopathological features in papillary thyroid carcinoma. Eur J Cancer 1992;29A:44-51.
21. Cunningham MP, et al. Survival discriminants for differentiated thyroid cancer. Am J Surg 1990;16:344-347.
22. Noguchi M, et al. Multivariate study of prognostic factors of differentiated thyroid carcinoma: the significance of histologic subtype. Int Surg 1993;78:10-15.
23. Schindler A, et al. Prognostic factors in papillary carcinoma of the thyroid. Cancer 1991;68:324-330.
24. Simpson WJ, et al. Papillary and follicular thyroid cancer: prognostic factors in 1578 patients. Am J Med 1987;83:479-488.
25. Tubiana M, et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985;55:794-804.
26. Hughes CJ, Shaha AR, Shah JP, Loree TR. Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched pair analysis. Head Neck 1996;18:127-132.
27. Shaha AR. Controversies in the management of thyroid nodule. Laryngoscope 2000;110(2, Part 1):183-193.
28. Clark OH. Total thyroidectomy: the treatment of choice for patients with differentiated thyroid cancer. Ann Surg 1982;196:361-370.
29. Carcangiu ML, et al. Papillary carcinoma of the thyroid: a clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer 1985;55:805-828.
30. Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 1998;83:2638-2648.
31. Shaha AR, Shah JP, Loree TR. Risk group stratification and prognostic factors in papillary carcinoma of the thyroid. Ann Surg Oncol 1996;3:534-538.
32. Shah JP, Loree TR, Dharker D, Strong EW, Begg C, Vlamis V. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg 1992;164:658-661.
33. Shah JP, Loree T, Dharker D, et al. Prognostic factors in differentiated carcinoma of the thyroid: a matched pair analysis. Am J Surg 1993;166:331-335.
34. Shaha AR, Shah JP, Loree TR. Patterns of nodal metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Am J Surg 1996;172:692-694.
35. Jossart GH, Clark OH: Well-differentiated thyroid cancer. Curr Prob Surg 1994;31:935-1011.
36. Mazzaferri EL. Management of the solitary thyroid nodule. N Engl J Med 1993;328:553-559.
37. Anderson PE, Kinsella J, Loree TR, Shaha AR, Shah JP. Differentiated carcinoma of thyroid with extrathyroidal extension. Am J Surg 1995;170:467-470.
38. Rosai J, Carcangiu ML, DeLellis RA. Tumors of the thyroid gland. In: Atlas of Tumor Pathology, 3rd series. Washington, DC: Armed Forces Institute of Pathology, 1992.
39. Moreno EA, Rodriguez Gonzales JM, Sola PJ, Soria CT, Parrilla PP. Prognostic value of the tall cell variety of papillary cancer of the thyroid. Eur J Surg Oncol 1993;19:517-521.
40. Czaja JM, McCaffrey TV. The surgical management of laryngotracheal invasion by well-differentiated papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 1997;123:484-490.
41. Grillo HC, Zannini P. Resectional management of airway invasion by thyroid carcinoma. Ann Thorac Surg 1986;42:287-298.
42. McCaffrey TV, Bergstralh EJ, Hay ID. Locally invasive papillary thyroid carcinoma: 1940-1990. Head Neck 1994;16:165-172.
43. Wenig BM, Thompson LDR, Adair CF, Shmookler B, Heffess CS. Thyroid papillary carcinoma of columnar cell type: a clinicopathological study of 16 cases. Cancer 1998;82:740-753.
44. Schroder S, Schwarz W, Rehpenning W, Loning T, Bocker W. Prognostic significance of Leu-M1 immunostaining in papillary carcinomas of the thyroid gland. Virchows Arch A Pathol Anat Histopathol 1987;41:435-439.
45. Asklen LA, Varhaug JE. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erb-B-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival. Cancer 1995;76:1643-1654.
46. Wasielewski RV, Rhein A, Werner M, et al. Immunohistorical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res 1997;57:2501-2507.
47. Cohn KH, Backdahl M, Forsslund G, et al. Biologic considerations and operative strategy in papillary thyroid carcinoma: arguments against the routine performance of total thyroidectomy. Surgery 1984;96:957-91.
48. Pasieka JL, Zedenius J, Auer G, et al. Addition of nuclear DNA content to the AMES risk-group classification for papillary thyroid cancer. Surgery 1992;112:1154-1160.
49. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 1993;91:1753-1760.
50. Godballe C, Asschenfelddt P, Jorgensen KE, et al. Prognostic factors in papillary and follicular thyroid carcinoma: p53 expression is a significant indicator of prognosis. Laryngoscope 1998;108:243-249.